Relay Therapeutics, Inc. (RLAY) Dividend History

Company News

• Healthcare's Quiet AI Boom Is Creating a New Class of Breakout Contenders

  The article discusses the rapid adoption of artificial intelligence (AI) in the healthcare industry, with several tech and biotech companies making significant strides. It highlights the potential of AI to transform various aspects of healthcare, including early disease detection and intelligent therapeutics.

  Benzinga

  Featured Companies: ATR BFLY
• Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival

  Relay Therapeutics announced updated interim data for its RLY-2608 drug in combination with fulvestrant, showing promising progression-free survival and response rates in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer.

  GlobeNewswire Inc.
• Why Relay Therapeutics Plummeted by Nearly 14% Today

  Relay Therapeutics, a biotech company developing oncology treatments, announced a secondary share offering of 28.6 million shares at $7 per share, which is seen as highly dilutive to existing shareholders. The stock fell nearly 14% in response, while the broader market gained over 1%.

  The Motley Fool
• Relay Therapeutics Announces Pricing of Public Offering of Common Stock

  Relay Therapeutics, a clinical-stage precision medicine company, announced the pricing of a $200 million public offering of its common stock. The offering is expected to close on September 12, 2024.

  GlobeNewswire Inc.
• Expert Ratings For Relay Therapeutics - Benzinga

  Relay Therapeutics (RLAY) underwent analysis by 5 analysts in the last quarter, with a downward trend in their average 12-month price target. The company's financial performance shows strong revenue growth, exceptional net margin, but below-industry benchmarks in market capitalization, return on equity, and return on assets.

  Benzinga